Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing.

Sørbye SW, Fismen S, Gutteberg T, Mortensen ES.

PLoS One. 2010 Sep 13;5(9):e12724. doi: 10.1371/journal.pone.0012724.

2.

High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ.

J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2.

3.

Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.

Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, Kovács K, Klozoris C, Bollmann R.

Oncol Rep. 2008 Feb;19(2):457-65.

PMID:
18202795
4.

HPV mRNA testing in triage of women with ASC-US cytology may reduce the time for CIN2+diagnosis compared with repeat cytology.

Sørbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE.

Curr Pharm Des. 2013;19(8):1401-5.

PMID:
23016772
5.

High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.

Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E, Andersson S.

Oncol Rep. 2012 Jul;28(1):346-52. doi: 10.3892/or.2012.1755. Epub 2012 Apr 3.

PMID:
22484610
6.

Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.

Perez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Diez MT, Cid Lama A, Alvarez Martín MJ, Pato Mosquera M, López-Miragaya I, Estévez N, Torres Piñón J, Oña Navarro M.

J Med Virol. 2013 Jun;85(6):1063-8. doi: 10.1002/jmv.23544.

PMID:
23588733
7.

Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.

Tropé A, Sjøborg KD, Nygård M, Røysland K, Campbell S, Alfsen GC, Jonassen CM.

J Clin Microbiol. 2012 Jun;50(6):1927-35. doi: 10.1128/JCM.00265-12. Epub 2012 Apr 18.

8.

Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M.

Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Epub 2013 Jul 23. Review.

9.

HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.

Duvlis S, Popovska-Jankovic K, Arsova ZS, Memeti S, Popeska Z, Plaseska-Karanfilska D.

J Med Virol. 2015 Sep;87(9):1578-86. doi: 10.1002/jmv.24199. Epub 2015 Apr 16.

PMID:
25880030
10.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
11.

HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.

Sørbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES.

PLoS One. 2011;6(10):e26022. doi: 10.1371/journal.pone.0026022. Epub 2011 Oct 6.

12.

Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients.

Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, Ronchetti L, Muti P, Mariani L, Sindico S, Vocaturo G, Vocaturo A.

Cancer Causes Control. 2011 Jun;22(6):869-75. doi: 10.1007/s10552-011-9757-0. Epub 2011 Mar 19.

PMID:
21424209
13.

Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.

Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, Di Franco A, Vellone VG, Durante M, Fadda G, Scambia G, Capelli G, De Vincenzo R.

J Clin Microbiol. 2009 Dec;47(12):3895-901. doi: 10.1128/JCM.01275-09. Epub 2009 Oct 14.

14.

Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.

Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, Terrenato I, Ciccocioppo L, Frega A, Giorgi Rossi P.

J Clin Microbiol. 2011 Jul;49(7):2643-50. doi: 10.1128/JCM.02570-10. Epub 2011 Apr 27.

15.

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A.

J Clin Microbiol. 2011 Feb;49(2):557-64. doi: 10.1128/JCM.02147-10. Epub 2010 Dec 8.

16.

Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.

Zappacosta R, Caraceni D, Ciccocioppo L, Rotondo T, Capanna S, Gatta DM, D'Angelo C, Rosini S.

Gynecol Oncol. 2013 Mar;128(3):427-32. doi: 10.1016/j.ygyno.2012.11.030. Epub 2012 Nov 28.

PMID:
23200910
17.

Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A.

J Clin Microbiol. 2010 Aug;48(8):2779-85. doi: 10.1128/JCM.00382-10. Epub 2010 Jun 23.

18.

Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.

Keegan H, Mc Inerney J, Pilkington L, Grønn P, Silva I, Karlsen F, Bolger N, Logan C, Furuberg L, O'Leary J, Martin C.

J Virol Methods. 2009 Jan;155(1):61-6. doi: 10.1016/j.jviromet.2008.09.027. Epub 2008 Nov 13.

PMID:
18955086
19.

Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.

Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F.

Acta Cytol. 2012;56(5):506-14. doi: 10.1159/000338979. Epub 2012 Sep 27.

PMID:
23075891
20.

Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US).

Waldstrom M, Ornskov D.

Cytopathology. 2012 Dec;23(6):389-95. doi: 10.1111/j.1365-2303.2011.00923.x. Epub 2011 Sep 20.

PMID:
21933290

Supplemental Content

Support Center